Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004907 · ClinicalTrials.gov registry record · Phase 1

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

A Phase 1 study, sponsored by Northwestern University.

Completed
Registry status
Phase 1
Development phase

NCT00004907 is a Phase 1 study that has completed, run by Northwestern University.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004907, a Phase 1 study, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and radiation therapy and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy and radiation therapy plus bone marrow or peripheral stem cell transplantation in treating patients who have refractory or relapsed T-cell lymphoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.

Interventions

  • DRUG cyclophosphamide
  • DRUG etoposide
  • DRUG busulfan
  • PROCEDURE allogeneic bone marrow transplantation
  • PROCEDURE bone marrow ablation with stem cell support

Trial Details

FieldValue
Start Date 1999-10
Est. Completion 2004-08
Phase Phase 1

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT00004907

The ClinicalTrials.gov registry entry for NCT00004907 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.

NCT00004907 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00004907 about?

NCT00004907 is a clinical study titled "Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy dru...

What is the current status of trial NCT00004907?

This trial is currently completed. It is a Phase 1 study. The study started on 1999-10. Estimated completion is 2004-08.

What interventions are being tested in trial NCT00004907?

The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), busulfan (DRUG), allogeneic bone marrow transplantation (PROCEDURE), bone marrow ablation with stem cell support (PROCEDURE).

Who is sponsoring clinical trial NCT00004907?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.